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Abstract
The inverse probability weighting (IPW) estimator is widely used to estimate the
treatment effect in observational studies in which patient characteristics might
not be balanced by treatment group. The estimator assumes that treatment as-
signment, is error-free, but in reality treatment assignment can be measured with
error. This arises in the context of comparative effectiveness research, using ad-
ministrative data sources in which accurate procedural or billing codes are not
always available. We show the bias introduced to the estimator when using error-
prone treatment assignment, and propose an adjusted estimator using a validation
study to eliminate this bias. In simulations, we explore the impact of the mis-
classified treatment assignment on the estimator, and compare the performance
of our adjusted estimator to an estimate based only on the validation study. We
illustrate our method on a comparative effectiveness study assessing surgical treat-
ments among Medicare beneficiaries, diagnosed with brain tumors. We use linked
SEER-Medicare data as our validation data, and apply our method to Medicare
Part A hospital claims data where treatment is based on ICD9 billing codes, which
do not accurately reflect surgical treatment.
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Abstract
The inverse probability weighting (IPW) estimator is widely used to estimate the treatment effect
in observational studies in which patient characteristics might not be balanced by treatment group.
The estimator assumes that treatment assignment, is error-free, but in reality treatment assignment
can be measured with error. This arises in the context of comparative effectiveness research, using
administrative data sources in which accurate procedural or billing codes are not always available.
We show the bias introduced to the estimator when using error-prone treatment assignment, and
propose an adjusted estimator using a validation study to eliminate this bias. In simulations, we
explore the impact of the misclassified treatment assignment on the estimator, and compare the
performance of our adjusted estimator to an estimate based only on the validation study. We
illustrate our method on a comparative effectiveness study assessing surgical treatments among
Medicare beneficiaries, diagnosed with brain tumors. We use linked SEER-Medicare data as our
validation data, and apply our method to Medicare Part A hospital claims data where treatment
is based on ICD9 billing codes, which do not accurately reflect surgical treatment.
Keywords
Causal Inference; Comparative Effectiveness Research; IPW Estimator; Measurement Error; Propen-
sity Score; Treatment Assignment; Validation Data.
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1 Introduction
There is a lot of interest in estimating causal treatment effects. Ideally, randomized control studies
would be used to study treatment effects, but not always these are feasible due to ethical reasons,
cost, time constraints, and compliance (among other reasons). Observational studies are more
widely available, however, involve some limitations. Since subjects are not randomized by treatment,
their characteristics might not be balanced by treatment group. In order to overcome this limitation,
propensity score based methods have been proposed (Rosenbaum and Rubin, 1983).
The propensity score is defined as the probability that an individual has been assigned to
treatment given their covariates. Various propensity score methods have been introduced including
subclassifying, matching, or weighing individuals by their propensity scores. Rosenbaum and Rubin
(1984) introduce a method that stratifies individuals based on their propensity score, and averages
the treatment effect across strata. Matching individuals by their propensity scores attempts to
create treated and control groups that have similar covariate values. Propensity scores can also be
used to weigh individuals observations (Rosenbaum, 1987). The focus of this work is on the inverse
probability weighting (IPW) estimator, which estimates the treatment effect, by weighing treated
individuals by their inverse propensity score and untreated individuals by the inverse of one minus
their propensity score (Rosenbaum, 2005).
The IPW estimator assumes that treatment assignment is measured without error, but in reality
treatment assignment in observational studies could be measured with error. Treatment assignment
in this context, can be thought of as the exposure variable. Standard techniques adjusting for
measurement error in exposures cannot be applied directly to this setting. Misclassification of
treatment assignment will lead to both error in the exposure variable directly, as well as error
in the propensity score estimates. Previous literature using propensity score methods has largely
focused on measurement error in confounders and missing confounders (McCaffrey and others, 2013;
McCandless and others, 2012; Stu¨rmer and others, 2005; Webb-Vargas and others, 2014).
Measurement error in the treatment assignment has been previously considered by Braun and
others (2014). They focus on likelihood-based methods to estimate the treatment effect, and con-
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sider three propensity score implementations (subclassificaiton, matching, and inverse probability
weighting). Under each of these implementations they describe in detail the impact of the misclas-
sified treatment on the three stages of the analysis (propensity score estimation, propensity score
implementation, and outcome analysis) and propose a likelihood-based approach to adjust for the
misclassification.
In contrast to Braun and others (2014) the focus of this work is on estimating the treatment effect
using the IPW estimator. Babanezhad and others (2010) consider a similar setting of mismeasured
exposures. Using estimating equations they derive the asymptotic bias for the IPW and doubly
robust estimators. This work differs from theirs in three main ways: 1) we do not approach
the problem using estimating equations as they do, instead we look at the estimator directly; 2)
their goal was to estimate the causal effect of a binary exposure, T and for an outcome, Y , they
focused on estimating the expected contrast β∗ = E(Y1 − Y0) (where Y1 = Y when T = 0 and
Y0 = Y when T = 1) based on the marginal structure mean model (Herna´n and others, 2002):
E(Yt) = β
∗t + α∗t = 0, 1 where α∗ = E(g(x)) and g(X) is an unknown function of the covariates
X. In contrast, our proposed approach does not use any model and estimates the conditional
effect ∆ = E(Y |T = 1, X) − E(Y |T = 0, X) directly. Thus, while they use a linear model to
relate outcome Y and the exposure T , our theoretical analysis is not restricted to a specific type of
outcome or model, and is therefore applicable to any outcome model.
The motivating data application is previously discussed in Braun and others (2014). Briefly,
our interest is in studying the treatment effect of two types of surgery (resection versus biopsy)
among Medicare beneficiaries diagnosed with malignant neoplasm of brain (brain tumors). We are
able to obtain Medicare Part A Hospital claims data, which is a large data set (41,971 individuals)
containing information on our outcome of interest (1-year mortality), the treatment assignment
(the determination of whether resection or a biopsy was preformed), as well as many confounders
(including age, gender, co-morbidities, etc). However, treatment assignment in this data set, is
based on ICD9 billing codes which are inaccurate. For a subset of individuals (5,463 individuals),
we are able to obtain data from SEER-Medicare, a cancer surveillance database with detailed
clinical information. Treatment assignment based on the procedural codes from SEER-Medicare is
4
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assumed to be more accurate, gold-standard (Chawla and others, 2014; Cooper and others, 2000;
Du and others, 2000). The SEER registry data managers review patient clinical charts to ascertain
these sort of differences, and do not use claims data in order to appropriately assign treatment
(biopsy vs. resection) received. The SEER-Medicare is our internal validation study.
Using a validation study, we propose an adjusted IPW estimator to estimate the treatment effect
in the main study. In Section 2 we introduce general notation, and then define the IPW estimator
and proposed adjusted estimator in Section 3. We perform simulations in Section 4, and apply our
method to data application in Section 5. Finally, we summarize the main results in Section 6.
2 General Notation
We use Y to denote the true outcome (ex: binary disease status, a continuous, categorical, or sur-
vival outcome), T to denote a true binary treatment (ex: surgical treatment assignment based on
procedural codes from SEER-Medicare), Tep to denote the error-prone binary treatment (ex: sur-
gical assignment based on ICD9 billing codes from Medicare Part A), and X to denote confounders
measured without error (ex: age, co-morbidity, etc).
We assume the main study (ex: Medicare Part A enrollees) consists of i = 1, ..., Nm individuals,
for which we observe Y, Tep and X. We assume the validation study (ex: SEER-Medicare enrollees)
consists of j = 1, ..., Nv individuals, where typically Nv < Nm, for which we observe T, Tep,X and
Y . We define N = Nm +Nv. Note that our work assumes settings of either an internal or external
validation study in which Y is observed.
The true propensity score is modeled by a Generalized Linear Model (GLM) relating T to X,
that is PStrue = E(T |X = x, γ) = g−1(γ0 + γT1 x), where g is known. Similarly, the error-prone
propensity score is modeled with: PSep = E(Tep|X = x, γep) = g−1(γ0ep + γT1epx). Propensity
scores estimated from these models will be denoted by ̂PStrue and P̂Sep respectively. To model
the measurement error model, we consider a GLM relating T to Tep and X, that is E(T |Tep,X) =
h−1(θ0 + θ1Tep + θT2 X) and let pim|n,X = P (T = n|Tep = m,X) n,m = 0, 1.
5
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3 IPW Estimator
Our interest is in estimating the true average treatment effect (ATE) on the outcome Y for the
entire population; ∆ = E[Y |T = 1,X]−E[Y |T = 0,X]. ∆ can be estimated from the observed data
under the following three assumptions: 1) (T, Y,X) are measured without error, 2) each individual
has a positive probability of being either treated or untreated: 0 < P (T = 1|X) < 1 for all X,
3) the treatment assignment is ignorable, so that, conditional on X, the potential outcomes are
independent of T : (Y0, Y1) ⊥ T |X (where Y0 is the outcome an individual would have had if he/she
were untreated, and Y1 is the outcome an individual would have had if he/she were treated).
3.1 Gold-Standard IPW Estimator
The IPW estimator gives an estimate of the treatment effect, by weighing treated individuals by
their inverse propensity score and untreated individuals by the inverse of one minus their propensity
score (Lunceford and Davidian, 2004; Rosenbaum, 2005). If the true treatment assignment, T , is
known, the IPW estimator would be:
∆ˆIPWtrue = N
−1
N∑
k=1
TkYk
P̂Strue,k
−N−1
N∑
k=1
(1− Tk)Yk
1− P̂Strue,k
The expected value of this estimator is E(Y1) − E(Y0) (Lunceford and Davidian, 2004), and thus
it provides an unbiased estimate of the true treatment effect.
3.2 Error-prone IPW Estimator
When the true treatment assignment is unknown in the main study, and only information on the
error-prone treatment assignment, Tep, is available, IPW estimator is error-prone and can be written
as:
∆ˆIPWep = N
−1
N∑
k=1
Tep,kYk
P̂Sep,k
−N−1
N∑
k=1
(1− Tep,k)Yk
1− P̂Sep,k
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We first show that this estimator is biased, and in the following section propose an approach to
adjust for the bias in the main study using the validation study. We begin by defining Y in terms
of potential outcomes, Y0 the outcome an individual would have had if he/she were untreated,
and Y1 the outcome an individual would have had if he/she were treated. Y can be written
as Y = TY1 + (1 − T )Y0. It follows that TepY = TepTY1 + Tep(1 − T )Y0 and (1 − Tep)Y =
(1− Tep)TY1 + (1− Tep)(1− T )Y0.
The expectation of each of the two components of the IPW estimator is taken separately. The
expectation of the first component of the estimator is:
E(
TepY
PSep
) = EE(
TepY
PSep
|Y1, Y0, X) = EE(TepTY1 + Tep(1− T )Y0
PSep
|Y1, Y0, X)
= EE(
TepTY1
PSep
|Y1, X) + EE(Tep(1− T )Y0
PSep
|Y0, X)
= E(
Y1
PSep
P (Tep = 1, T = 1|Y1, X)) + E( Y0
PSep
P (Tep = 1, T = 0|Y0, X))
Similarly, the expectation of the second component of the estimator is:
E(
(1− Tep)Y
PSep
) = EE(
(1− Tep)Y
1− PSep |Y1, Y0, X) = EE(
(1− Tep)TY1 + (1− Tep)(1− T )Y0
1− PSep |Y1, Y0, X)
= EE(
(1− Tep)TY1
1− PSep |Y1, X) + EE(
(1− Tep)(1− T )Y0
1− PSep |Y0, X)
= E(
Y1
1− PSepP (Tep = 0, T = 1|Y1, X)) + E(
Y0
1− PSepP (Tep = 0, T = 0|Y0, X))
Thus, overall, the expectation of the error-prone IPW estimator is:
E(∆IPWep) = E(
Y1
PSep
P (Tep = 1, T = 1|Y1, X)) + E( Y0
PSep
P (Tep = 1, T = 0|Y0, X))
− E( Y1
1− PSepP (Tep = 0, T = 1|Y1, X))− E(
Y0
1− PSepP (Tep = 0, T = 0|Y0, X))
Under two additional assumptions; 1) that the measurement error model is independent of
outcome; P (T = n|Tep = m,Ym,X) = P (T = n|Tep = m,X), n = 0, 1 m = 0, 1, 2) that the
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error-prone treatment assignment is ignorable, so that, conditional on X, the potential outcomes
are independent of Tep: (Y0, Y1) ⊥ Tep|X. , the expectation of the error-prone IPW estimator in
the main study reduces to:
E(∆IPWep) = E(Y1pi1|1,X) + E(Y0pi0|1,X)− E(Y1pi1|0,X)− E(Y0pi0|0,X) (1)
This estimator is clearly biased, and would be unbiased only when pi1|1,X = 1 and pi0|0,X = 1,
that is if there is no misclassification. Note, the work considered by Babanezhad and others (2010)
is a special case of Equation 1, under the assumption that E(Y1−Y0) = β∗, where β∗ is the expected
contrast.
3.3 Adjusted IPW Estimator
One proposed approach to eliminate the bias caused by using the error-prone treatment, shown
in Equation (1), involves two steps. First, the division of the first component of the estimator in
Equation (1) by pi1|1,X and the second component of the estimator by pi0|0,X. The expected value
of this new estimator would be:
E(
Y1pi1|1,X
pi1|1,X
) + E(
Y0pi0|1,X
pi1|1,X
)− E(Y1pi1|0,X
pi0|0,X
)− E(Y0pi0|0,X
pi0|0,X
)
= E(Y1) + E(
Y0pi0|1,X
pi1|1,X
)− E(Y1pi1|0,X
pi0|0,X
)− E(Y0)
This first step is not sufficient to eliminate the bias. Two components, E(
Y0pi0|1,X
pi1|1,X
) and E(
Y1pi1|0,X
pi0|0,X
)
contribute to this remaining bias. The proposed second step involves estimating these two bias
components in the validation data, and subtracting them from the overall estimator.
Thus, the proposed adjusted estimator in the main study can be written as:
∆ˆIPWadj−main = N
−1
m
Nm∑
i=1
Tep,iYi
P̂Sep,i ̂pi1|1,X −N−1m
Nm∑
i=1
(1− Tep,i)Yi
(1− P̂Sep,i) ̂pi0|0,X
8
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− N−1v
Nv∑
j=1
(1− Tj)Yj
(1− P̂Strue,j)
̂pi0|1,X̂pi1|1,X
+ N−1v
Nv∑
j=1
TjYj
P̂Strue,j
̂pi1|0,X̂pi0|0,X (2)
The expected value of this estimator is E(Y1)−E(Y0), and thus this estimator is unbiased. The
first two sums in Equation (2) are calculated for the main study, however the measurement error
model pi1|1,X and pi0|0,X will be estimated in the validation study. Thus, the proposed estimator
relies on the transportability assumption. This is a common assumption in the measurement error
literature assuming that the measurement error model is transportable from the validation study
to the main study.
The overall adjusted IPW estimator for the entire population can be written as:
∆ˆIPWadj = ω(N
−1
m
Nm∑
i=1
Tep,iYi
P̂Sep,i ̂pi1|1,X −N−1m
Nm∑
i=1
(1− Tep,i)Yi
(1− P̂Sep,i) ̂pi0|0,X
− N−1v
Nv∑
j=1
(1− Tj)Yj
(1− P̂Strue,j)
̂pi0|1,X̂pi1|1,X +N−1v
Nv∑
j=1
TjYj
P̂Strue,j
̂pi1|0,X̂pi0|0,X )
+ (1− ω)
N−1v Nv∑
j=1
TjYj
P̂Strue,j
−N−1v
Nv∑
j=1
(1− Tj)Yj
1− P̂Strue,j

= ω∆ˆIPWadj−main + (1− ω)∆ˆIPWtrue−val (3)
where ∆ˆIPWtrue−val is the IPW estimator based on the true treatment assignment in the vali-
dation study. One common choice for ω is Nm/N , however, we propose instead to use an ωˆ that
minimizes the variance of ∆ˆIPWadj . Let V1 be the variance of ∆ˆIPWadj−main , V2 be the variance
of ∆ˆIPWtrue−val , and V12 indicate the covariance of the two estimators (ρ
√
V1V2, where ρ is the
correlation of the two estimators).
var(ω∆ˆIPWadj−main + (1− ω)∆ˆIPWtrue−val) = ω2V1 + (1− ω)2V2 + 2ω(1− ω)V12 = Vω (4)
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Minimizing Equation 4, we obtain ωˆ = V2−V12V1+V2−2V12 . Therefore we propose using the adjusted
estimator in Equation 3 with ωˆ = Vˆ2− ˆV12
Vˆ1+Vˆ2−2 ˆV12 . Vˆ1, Vˆ2, and Vˆ12 are obtained by bootstrapping with
500 bootstrap samples.
4 Simulations
The goal of our simulations is to study the effects of measurement error in the treatment assignment
on the IPW estimator. Performance of our proposed estimator is evaluated by comparing treatment
effect estimates for the validation study, main study, and overall population based on true treatment
assignment (gold standard, Equation (1)), error-prone treatment assignment (naive, Equation (1)),
and the proposed adjusted estimator (Equation (3)).
4.1 Simulation Characteristics
For each simulation scenario we simulated two data sets in a similar manner, one to be used as
the main study and one to be used as validation data. We simulated the main study with Nm
individuals and the validation study with Nv individuals. We generate two continuous confounders
X = (1, X1, X2). Tep was generated as Bernoulli according to the error-prone propensity score
logit(P (Tep = 1|X1)) = γ0 + γ1X1. T was generated as Bernoulli according to the measurement
error model logit(P (T = 1|Tep, X2)) = η0 +η1T +η2X2. Y was generated as Bernoulli according to
the outcome model logit(P (Y = 1|T,X)) = β0+β1T+β2X2. β = (β0, β1, β2)T = (−0.3, 10,−0.6)T ,
so that β1 = 10. We consider γ = (γ0, γ1)
T = (0.5,−0.3)T . For the measurement error model,
we consider η = (η0, η1, η2)
T = (0.2, 10,−0.1). In addition, six sample sizes were considered 1)
Nm = 3, 000 and Nv = 1, 500, 2) Nm = 5, 000 and Nv = 1, 000, 3) Nm = 4, 000 and Nv = 1, 000, 4)
Nm = 3, 000 and Nv = 1, 000, 5) Nm = 2, 000 and Nv = 1, 000, and 6) Nm = 2, 000 and Nv = 500,
. After the data was generated, we applied the analysis strategies described in previous sections.
100 repetitions were performed for each scenario. For each of the 100 repetitions, 500 bootstrap
samples were used to obtain estimates of V1, V2, and V12.
10
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4.2 Simulation Results
Figure 1 evaluates the effects of measurement error using the IPW estimator. We present detailed
results for one sample size combination, Nm = 5, 000 and Nv = 1, 000 (Figure 1), the remaining
results are reported in the Web Appendix (Web Figures 1-5). From left to right, we plot results
based on the validation study, main study, and overall study population. For each study population
we calculate the ATE based on the true treatment assignment (GS), and based on the error-prone
treatment assignment (EP). For the overall study population, we also calculate the ATE based on
the proposed adjustment (Equation 3).
Across all study populations, the ATE is unbiased when using the gold standard treatment
assignment, and biased when using the error-prone treatment assignment. Our main interest is in
two potential estimators, the first using the gold standard based only on the validation study, and
the second is our proposed adjustment using both the main and validation studies (Overall: Adj
in Figure 1). Using the gold standard based only on the validation study, the ATE is unbiased,
and the variance is 0.001331. The proposed adjusted is also unbiased, and the variance reduces to
0.000775. Thus, our proposed adjustment provides a 42% decrease in variance.
5 Data Application
We apply the adjusted estimator proposed in this paper, to determine the treatment effect of
resection versus biopsy on one year mortality for Medicare beneficiaries ages 65 and older, diagnosed
with malignant neoplasm of brain between 1999 and 2007. We use the Medicare dataset as our
main study, and the SEER-Medicare dataset as our internal validation study. We focus on a subset
of the population which had either a resection or biopsy performed. Patients in the SEER-Medicare
dataset are also included in the Medicare Part A dataset, but linkage across sources is unidentifiable,
so we cannot determine the Part A record corresponding to each SEER-Medicare record. For this
reason, we decide to limit the Medicare Part A dataset to individuals diagnosed in even years, and
the SEER-Medicare dataset to individuals diagnosed in odd years, thus ensuring that the same
individual is not included in both datasets. In addition, to make the two study populations more
11
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comparable, we decide to limit our analysis to patients in Medicare Part A that are in the subset
of states included in SEER-Medicare. We also exclude patients diagnosed with other forms of
cancer, allowing us to more accurately evaluate the effect of this specific treatment on mortality.
The final Medicare Part A dataset used for the analysis consisted of 11,036 patients, and the final
SEER-Medicare consisted of 1,582 patients.
We select confounders with at least 2% prevalence in both cohorts for the analysis. This is
described in detail in Braun and others (2014), and summaries of patient characteristics of the two
cohorts are shown in Table 1 (this table also appears in (Braun and others, 2014)). Error-prone
resection rates are higher in SEER-Medicare compared to Medicare Part A (92.0% vs. 62.8%,
p < 2.2× 10−16 ), and mortality rates are lower in SEER-Medicare compared to Medicare Part A
(72.6% vs. 81.5%, p < 2.2 × 10−16). Patient characteristics across some of the confounders also
differ across the cohorts.
Our proposed adjustment assumes the measurement error model is transportable from the val-
idation study to the main study. We hypothesize that errors in the appropriate coding of neuro-
surgical biopsy vs. resection may be related to important but subtly distinct definitions of biopsy
vs. subtotal resection within the brain. These differences are likely not the focus of physicians or
administrators handling claims, and thus any erroneous or misclassified ICD-9 codes used for these
two procedures should arise similarly for the Medicare component of the Part A dataset as well
as the SEER-Medicare linkage. Therefore, we believe that this transportability assumption likely
holds since the mechanism driving the error is likely similar in the two populations.
5.1 Data Analysis Results
The measurement error model, E(T |Tep,X) = h−1(θ0+θ1Tep+θT2 X), where h is logit, is estimated
in the SEER-Medicare data. We then apply our correction the Medicare Part A dataset. Results
from this analysis are shown in Table 2. We compare the ATE based on the error-prone IPW
estimator to the proposed adjusted IPW estimator. We see that the ATE stays the same after the
adjustment (from −0.11 95% CI: (−0.12,−0.10) to −0.10 95% CI: (−0.17,−0.03). In addition, we
conducted a sensitivity analysis to assess how sensitive the proposed adjustment is to the trans-
12
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portability assumption. We estimated θˆ in the SEER-Medicare validation study, and then sampled
100 different samples, θ̂sens, from a normal distribution with mean θˆ and standard deviation equal
to standard error estimates of θˆ multiplied by one, two, or five. These results are presented in
Table 3 and show when there is small variability in the estimates of θ (standard error estimates of
θˆ multiplied by one) the adjustment yields similar results, but as variability in θ increases results
quickly become less consistent.
6 Discussion
In this paper we present an approach to adjust for measurement error in treatment assignment in
observational studies. We derive the bias in the IPW estimator, propose an adjusted estimator,
and evaluate the performance of the adjusted estimator in simulations with finite sample sizes.
Simulation studies show that, when we adjust for confounding using IPW, the proposed esti-
mator (defined in Equation (3)) is appropriate and performs as well as the gold standard in terms
of bias. In addition, the proposed estimator provides a variance reduction compared to the naive
approach of using the gold standard based on the validation study only.
The proposed estimator relies on a transportability assumption, which requires careful thought.
In our data application, it is reasonable to assume that the mechanism driving the error is the
same for the two populations, as discussed in Section 5. In our data application we assume that
treatment assignment based on SEER-Medicare is the gold standard, however, surgical treatment
assignment in patients with malignant neoplasm of brain is complex. Surgeons will often decide
whether to perform a more extensive tumor resection vs. only a biopsy, which includes removing
less tumor tissue, only once they are in the operating room, based on nearby critical brain regions.
In addition, the line between these two procedures is often ambiguous, and even among surgeons
performing the same procedure there could be discrepancies in coding. Thus, even the SEER-
Medicare procedural codes might not be an absolute gold-standard, which is a limitation. However,
these codes do provide more accurate information compared to ICD-9 codes, are the best treatment
assignment variables available and permit an illustration of our methods showing the impact of the
13
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measurement error adjustment.
The IPW estimator is widely used in the literature. Measurement error in exposure, treatment
assignment, is often ignored (Jurek and others, 2006). This paper proposes a direct approach to
estimate the bias, and eliminate it. It is easy to implement, and can be implemented in a wide
range of scenarios in which validation data is available.
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Figure 1: ATE estimator, across 100 simulations for sample size Nm = 5, 000 and Nv = 1, 000.
GS (Gold Standard) is based on the true treatment assignment. EP (Error Prone) is based on the
error-prone treatment assignment. Adj is based on the error-prone treatment assignment with the
proposed adjusted estimator, with ωˆ. V1, V2, V12 were estimated based on 500 bootstrap samples
for each simulation. The true ATE is marked in red.
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Table 1: Medicare Part A and SEER-Medicare Population Characteristics
Medicare Part A SEER-Medicare P-value
Population Size 11,036 1,582 –
1-year mortality events 8,989 (81.5%) 1,148 (72.6%) < 2.2× 10−16
Error-prone Resection based on ICD9 codes 6,928 (62.8%) 1,453 (92.0%) < 2.2× 10−16
True Resection based on SEER-Medicare - 1,242 (78.5%) –
Age 74.77 73.67 8× 10−12
Female 47.1% 46.6% 0.69
Dual Eligible 7.4% 6.1% 0.06
Brain MRI 9.1% 15.1% 4× 10−14
Head CT 6.6% 6.7% 0.93
Radiotherapy Inpatient ICD9 2.9% 8.2% < 2× 10−16
Atherosclerosis 20.5% 14.7% 4× 10−8
Substance Abuse 8.0% 6.2% 0.01
Hypertension 60.0% 57.7% 0.09
COPD 12.0% 9.4% 0.002
Dementia 10.2% 5.6% 1× 10−8
Trauma 4.2% 3.1 % 0.05
Psychological Disorder 3.7% 2.8% 0.06
Depression 7.0% 5.6% 0.04
Seizure Disorder 20.4% 21.7% 0.24
Asthma 3.1% 2.3% 0.08
Valvular/Rheumatic Heart Disease 5.7% 4.0% 0.005
Diabetes 18.0% 16.4% 0.11
Region: West 15.8% 45.3% < 2.2× 10−16
Region: Midwest 26.9% 15.2% < 2.2× 10−16
Region: Northeast 19.3% 22.6% 0.002
Region: South 28.0% 16.8% < 2.2× 10−16
Admission Type: Emergency 34.9% 33.8% 0.37
Admission Type: Urgent 23.5% 24.2% 0.54
Admission Type: Elective 41.6% 42.0% 0.74
Admission Source: Clinic 52.5% 51.6% 0.51
Admission Source: HMO 4.0% 4.4% 0.42
Admission Source: SNF 10.0% 10.0% 0.96
Admission Source: Court/Law 31.2% 31.9% 0.55
Admission Source: Other 2.3% 2.1% 0.55
Table 2: ATE of resection vs. biopsy in Medicare Part A/SEER-Medicare Data Application,
Outcome 1-year mortality
ATE [95% CI]
SEER/Medicare: true trt -0.03 [-0.07, 0.03]
Medicare Part A: ep trt -0.11 [-0.13, -0.10]
Medicare Part A: adj -0.10 [-0.17, -0.05]
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Table 3: Sensitivity analysis for estimating ATE of resection vs. biopsy in Medicare Part A Data
Application, Outcome 1-year mortality. After estimating θˆ in the SEER-Medicare validation study,
100 different samples, θ̂sens were sampled from a normal distribution with mean θˆ and standard
deviation equal to standard error estimates of θˆ multiplied by one, or two.
Sensitivity Analysis
ATE [95% CI]
Medicare Part A: Adj. σ -0.09 [-0.30, 0.12]
Medicare Part A: Adj. ∗2σ 0.39 [-2.11, 1.99]
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